Volume 10, Issue 1 (1-2020)                   Iran J Ped Hematol Oncol 2020, 10(1): 49-56 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Naghibzadeh R, Obeidi N, Farsinejd A, Khamisipour G, Tohid Far M. Effect of Estradiol on miR-21& miR-155 Expression in promyelocytic leukemia-derived cell line NB4. Iran J Ped Hematol Oncol 2020; 10 (1) :49-56
URL: http://ijpho.ssu.ac.ir/article-1-454-en.html
Department of Hematology, School of Para Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
Abstract:   (1912 Views)
Background: Due to the estrogen participation in modulating the proliferation and commitment of stem cells and the effects of miR-21 and miR-155 expression on reduced proliferation and colony formation of acute myeloid leukemia (AML), the aim of the present study was to evaluate the effect of estradiol on expression of miR-21 and miR-155 in the NB4 cell line, as an acute promyelocytic leukemia (APL).
Materials and Methods: In the present experiment, NB4 cells were treated with different quantities of estradiol (5, 25, 50, 75, 100, 150, 200, 250 μg/ml) and vehicle control for 24 and 48 hours. Viability, apoptosis, and cellular proliferation were estimated by trypan blue exclusion, flow cytometry, and MTT assays, respectively. The level of miR-155 and miR-21 expression was studied using absolute quantitative real-time PCR.
Results: Results showed that estradiol in the effective dose (200 μg/ml) led to decreased cellular viability (in a dose dependent manner, P = 0.004) and apoptosis of NB4 cells. In addition, the expressions of miR-155 and miR-21 were significantly and dose-dependently decreased (p<0.05).
Conclusion: Estradiol at the effective dose caused apoptosis in NB4 cell line. This substance can be used as a drug for the treatment of APL. However, further assessments are needed to support the effectiveness of estradiol in the treatment of APL.
 
Full-Text [PDF 289 kb]   (616 Downloads)    
Type of Study: Research | Subject: General
Received: 2019/03/25 | Accepted: 2019/11/10 | Published: 2020/01/6

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Pediatric Hematology and Oncology

Designed & Developed by : Yektaweb